SNIP Will Back French Spending Curbs

29 September 1996

Bernard Mesure, president of the French drug industry association, the SNIP, says the industry has proved it is a "loyal partner" of the government policy to control health spending, but wants measures announced in 1995 to take effect. He says the new industry/government negotiations on drug prices to renew the framework agreement should start in October, well ahead of the expiry of the existing deal on December 31.

Drug sales have slowed their rate of rise year-on-year since the start of second-quarter 1996, falling 6% to a little under 3% in July and August, very close to the target growth of 2.1% set by the government for general medical treatment.

Mr Mesure said the industry's provision of the required "exceptional contribution" of 2.5 billion French francs was "a drop of water" in relation to the social security deficit. The industry now expects the measures announced in 1995 to be put into operation. Among these, the system of medical guidelines for prescribing doctors, intended to be available this year, has been awaited since last January.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight